Under the partnership, IBM will develop algorithms to determine a child’s risk of developing Type 1 diabetes based on genetic, familial and autoantibody factors. The organizations’ goal is to “create an entry point for T1D in the field of precision medicine” by identifying predictive factors that might delay or prevent Type 1 diabetes onset in children, according to an IBM statement.
“Nearly 40,000 new cases of Type 1 diabetes will be diagnosed in the U.S. this year. And each new patient creates new records and new data points that, if leveraged, could provide additional understanding of the disease,” said Jianying Hu, PhD, senior manager and program director of the center for computational health at IBM Research.
More articles on health IT:
NIH provides up to $14.8M for pediatric data resource center
Allscripts, Elligo Health Research partner to streamline clinical trials
Can AI improve cancer care in remote areas? 3 questions with Dr. Andrew Norden of IBM Watson Health
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
